Skip to content

Search

Showing results for "Childhood interstitial lung disease "

Safety and Immunogenicity of Early Quadrivalent Influenza Vaccine: A phase 2prospective randomised open-label feasibility study (FluBub)

Young children, particularly those younger than six (6) months are at increased riskof severe influenza infection.

A new job for a specialised drug

The Kids is investigating whether a cystic fibrosis medication may be the answer to ear infections, reducing the need for antibiotics and surgery.

One in six kids found to have Strep A throughout Kimberley region

An alarming number of Strep A infections are going unnoticed throughout classrooms in Broome and Derby according to a major study by The Kids Research Institute Australia aiming to reduce the burden of acute rheumatic fever (ARF) and rheumatic heart disease (RHD).

Large-scale study of epigenetic landscape to understand and overcome diabetes in Indigenous Australians

A large-scale study of the epigenetic landscape of Indigenous Australians could help tackle chronic diseases faced by Aboriginal and Torres Strait Islander people.

The Kids Research Institute Australia researcher wins Premier’s Science Award

Infectious diseases researcher, Dr Asha Bowen, has won the Early Career Scientist of the Year Premier's Science Award for 2017.

Insights from a trial of narrowband UVB for early multiple sclerosis

There is a greater prevalence of multiple sclerosis (MS), a neurological autoimmune condition, in populations living further from the equator, hypothesised to be due to reduced sunlight exposure. There exists a proven sunlight surrogate therapy for dermatological inflammatory conditions, in the form of narrowband NB-UVB phototherapy. Yet, there is a paucity of randomized trials of the therapeutic delivery of NB-UVB beyond dermatology for conditions with a systemic inflammatory component. 

Respiratory Syncytial Virus Reinfections in Children in Western Australia

Respiratory syncytial virus (RSV) reinfection in children is poorly understood. We examined the incidence, characteristics, and outcomes of hospital-attended RSV reinfections in children <16 years in Western Australia between 2012 and 2022.

Respiratory syncytial virus in children: epidemiology and clinical impact post-COVID-19

Respiratory syncytial virus (RSV) remains a leading cause of mortality and morbidity worldwide. RSV seasonality was disrupted by COVID-19-associated nonpharmaceutical interventions (NPIs). We review RSV seasonality, molecular epidemiology, clinical manifestations, and community awareness to inform future prevention strategies. 

Influenza hospitalizations in Australian children 2010–2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness

Children with comorbidities are at greater risk of severe influenza outcomes compared with healthy children. In Australia, influenza vaccination was funded for those with comorbidities from 2010 and all children aged <5 years from 2018. Influenza vaccine coverage remains inadequate in children with and without comorbidities.

Integrate, Identify, Intervene (Triple I Project): Identifying opportunities for preventing respiratory infections in children through integrating population-based health and laboratory data

Christopher Hannah Blyth Moore MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers Centre of Vaccines and